NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free XNCR Stock Alerts $20.58 -0.73 (-3.43%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$20.39▼$21.1150-Day Range$18.21▼$24.5052-Week Range$16.49▼$26.84Volume511,742 shsAverage Volume553,953 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$35.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Xencor alerts: Email Address Xencor MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.9% Upside$35.38 Price TargetShort InterestHealthy9.05% of Shares Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment0.18Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.50) to ($3.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.12 out of 5 starsMedical Sector127th out of 915 stocksPharmaceutical Preparations Industry51st out of 430 stocks 4.5 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXencor has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xencor's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.05% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Xencor has recently decreased by 11.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 2.3 News and Social Media Coverage News SentimentXencor has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Xencor this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows1 people have added Xencor to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.23% of the stock of Xencor is held by insiders.Read more about Xencor's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.50) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -9.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -9.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Xencor's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About Xencor Stock (NASDAQ:XNCR)Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Read More XNCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XNCR Stock News HeadlinesJune 15 at 6:16 AM | americanbankingnews.comXencor (NASDAQ:XNCR) Price Target Lowered to $31.00 at Royal Bank of CanadaJune 15 at 2:44 AM | americanbankingnews.comWedbush Reaffirms "Outperform" Rating for Xencor (NASDAQ:XNCR)June 13 at 8:01 AM | businesswire.comXencor Regains CD20 x CD3 Bispecific T-Cell EngagerJune 12 at 7:20 AM | americanbankingnews.comXencor (NASDAQ:XNCR) Shares Gap Down to $21.74May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xencor: Strong Q1 Financials, FDA Approval, and Promising Pipeline Signal Growth PotentialMay 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xencor on Strategic Focus and Strong Financial PositionMay 11, 2024 | finance.yahoo.comXencor First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | markets.businessinsider.comDecoding 6 Analyst Evaluations For XencorMay 10, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on Xencor (XNCR)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xencor on Strong Pipeline and Financials: Anticipated IND Filing and T-cell Engager DevelopmentsMay 10, 2024 | finance.yahoo.comXencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings EstimatesMay 10, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Xencor (XNCR) and Evolent Health (EVH)May 10, 2024 | investorplace.comXNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | businesswire.comXencor Reports First Quarter 2024 Financial ResultsMay 3, 2024 | finance.yahoo.comInsider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells SharesApril 16, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For XencorApril 11, 2024 | uk.investing.comXencor names Bart Cornelissen as new CFOApril 10, 2024 | markets.businessinsider.comXencor Appoints Bart Cornelissen As CFOApril 9, 2024 | marketwatch.comXencor Names Bart Cornelissen Chief Financial OfficerApril 9, 2024 | finance.yahoo.comXencor Appoints Bart Cornelissen as Chief Financial OfficerApril 9, 2024 | businesswire.comXencor Appoints Bart Cornelissen as Chief Financial OfficerMarch 16, 2024 | finance.yahoo.comXNCR Apr 2024 30.000 callMarch 9, 2024 | finance.yahoo.comXNCR May 2024 22.500 putMarch 7, 2024 | finance.yahoo.comInsider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)March 1, 2024 | markets.businessinsider.comXencor’s Strategic Focus and Pipeline Progress Affirm Buy RatingSee More Headlines Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/15/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Stock Price Target$35.38 High Stock Price Target$50.00 Low Stock Price Target$24.00 Potential Upside/Downside+71.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,090,000.00 Net Margins-82.23% Pretax Margin-79.16% Return on Equity-20.29% Return on Assets-15.72% Debt Debt-to-Equity Ratio0.02 Current Ratio7.08 Quick Ratio7.08 Sales & Book Value Annual Sales$168.34 million Price / Sales7.54 Cash FlowN/A Price / Cash FlowN/A Book Value$10.99 per share Price / Book1.87Miscellaneous Outstanding Shares61,660,000Free Float58,438,000Market Cap$1.27 billion OptionableOptionable Beta0.82 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Bassil I. Dahiyat Ph.D. (Age 54)Co-Founder, CEO, President & Director Comp: $1.07MDr. John R. Desjarlais Ph.D. (Age 60)Executive VP of Research & Chief Scientific Officer Comp: $748.65kMs. Celia E. Eckert J.D. (Age 51)Senior VP, General Counsel & Corporate Secretary Comp: $641.85kDr. Nancy Valente M.D. (Age 65)Executive VP & Chief Development Officer Comp: $797.68kMr. Bart Jan CornelissenSenior VP & CFOMr. Charles LilesAssociate Director and Head of Corporate Communications & Investor RelationsMs. Jennifer SandozSenior VIce President of Human ResourcesDr. Jeremy Grunstein Ph.D.Senior Vice President of Business DevelopmentMr. Kirk Rosemark RAC (Age 59)Senior Vice President of Regulatory Affairs & Quality Assurance Mr. Eric P. KowackSenior Vice President of Program Leadership & Alliance ManagementMore ExecutivesKey CompetitorsKura OncologyNASDAQ:KURAZymeworksNYSE:ZYMEAimmune TherapeuticsNASDAQ:AIMTMacroGenicsNASDAQ:MGNXPrelude TherapeuticsNASDAQ:PRLDView All CompetitorsInsiders & InstitutionsComerica BankSold 2,736 shares on 5/17/2024Ownership: 0.036%Jacobs Levy Equity Management Inc.Bought 208,227 shares on 5/16/2024Ownership: 0.338%Silvercrest Asset Management Group LLCBought 6,294 shares on 5/16/2024Ownership: 0.234%California State Teachers Retirement SystemSold 2,984 shares on 5/16/2024Ownership: 0.089%Baker BROS. Advisors LPBought 300,000 shares on 5/15/2024Ownership: 0.885%View All Insider TransactionsView All Institutional Transactions XNCR Stock Analysis - Frequently Asked Questions Should I buy or sell Xencor stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XNCR shares. View XNCR analyst ratings or view top-rated stocks. What is Xencor's stock price target for 2024? 8 brokers have issued 12 month price objectives for Xencor's shares. Their XNCR share price targets range from $24.00 to $50.00. On average, they anticipate the company's stock price to reach $35.38 in the next year. This suggests a possible upside of 71.9% from the stock's current price. View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts. How have XNCR shares performed in 2024? Xencor's stock was trading at $21.23 on January 1st, 2024. Since then, XNCR stock has decreased by 3.1% and is now trading at $20.58. View the best growth stocks for 2024 here. When is Xencor's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our XNCR earnings forecast. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) issued its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.28. The biopharmaceutical company had revenue of $12.80 million for the quarter, compared to the consensus estimate of $23.07 million. Xencor had a negative trailing twelve-month return on equity of 20.29% and a negative net margin of 82.23%. The firm's revenue for the quarter was down 32.3% compared to the same quarter last year. During the same period last year, the firm posted ($1.02) EPS. What ETFs hold Xencor's stock? ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Loncar China Biopharma ETF (CHNA), Range Cancer Therapeutics ETF (CNCR), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares Genomics Immunology and Healthcare ETF (IDNA). What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN). Who are Xencor's major shareholders? Xencor's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.37%), Price T Rowe Associates Inc. MD (6.19%), Darwin Global Management Ltd. (1.80%), Baker BROS. Advisors LP (0.88%), Principal Financial Group Inc. (0.53%) and Russell Investments Group Ltd. (0.36%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais and Kurt A Gustafson. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XNCR) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.